Diligence memo · auto-generated · as of July 2, 2026
Normunity Holding Company, LLC
Normunity Holding Company, LLC looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Normunity Holding Company, LLC operates in Biotechnology, based in Boston.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Normunity Holding Company, LLC has raised $83M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $46M on 2022-01-11.
Most recent recorded round closed around 2025-01-10.
Valuation (modeled)modeled
Provath models Normunity Holding Company, LLC at approximately $274M (range $116M–$386M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.42× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era. Within the normal band (142% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 36 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 88% of Biotechnology peers (4293 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.